Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISTINCT: Individualized versus standard thrombosis prophylaxis after total hip or knee arthroplasty
2023-510186-98-00Phase 4Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of apixaban in venous thromboembolism (VTE) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Number of venous thromboembolic events and Number of major bleeding events. Planned start Aug 2024; status: authorised.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2023-510186-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510186-98-00.